• Health Canada authorized Optimi Health’s Phase 3 trial of MDMA-assisted therapy for PTSD, with up to 100 participants.
• Enrollment targets veterans, current or former frontline workers across multiple Canadian sites.
• Study is expected to start in 2027, using two supervised MDMA dosing sessions with psychotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006065), on September 16, 2026, and is solely responsible for the information contained therein.